Highlights d TGF-b has opposing effects in different breast-tumorinitiating cell (BTIC) types d Genomic SMAD3 binding patterns are similar in BTICs with opposing responses to TGF-b d BTIC type-specific epigenomes prime genes for regulation by TGF-b/SMAD3 d LBH, a type-specific TGF-b target, is essential for BTICpromoting effects of TGF-b
In Brief
The TGF-b pathway uses transcriptional regulation through SMAD transcription factors to modulate cell-context-specific phenotypes. Tufegdzic Vidakovic et al.
show that in breast-tumor-initiating cells (BTICs), type-specific DNA and histone modifications help determine whether the response to TGF-b is pro-oncogenic or tumor suppressive. These landscapes act both in synergy and independently of celltype-specific SMAD3 binding to TGF-b target genes to modulate context-specific transcriptional regulation by TGF-b/ SMAD3.
INTRODUCTION
The effects of transforming growth factor beta (TGF-b) in tissue homeostasis depend heavily on cellular context (Massagué , 2012) . TGF-b has been shown to both induce proliferation and suppress cell growth, stimulate stem cell self-renewal and promote differentiation, and inhibit early and promote late malignant transformation (Gomis et al., 2006; Guasch et al., 2007; Massagué , 2008 Massagué , , 2012 .
In breast cancer, TGF-b can either promote or inhibit tumorinitiating cells (breast TICs, or BTICs), which are responsible for cancer initiation, propagation, and metastasis (Bierie and Moses, 2009; Bruna et al., 2012; Mani et al., 2008; Scheel et al., 2011) . We have previously shown these opposing effects of TGF-b depend on breast cancer subtype (Bruna et al., 2012) . BTICs are activated only in Claudin low breast cancer, while in all other subtypes, TGF-b inhibits BTICs. Since no muta-tions in TGF-b pathway genes have been associated with specific breast cancer subtypes (Cancer Genome Atlas Network, 2012) , the underlying mechanism of this dichotomy is unlikely to be genetic.
TGF-b signaling is initiated by binding of TGF-b to its cognate receptor, TGFBR II, resulting in phosphorylation of the transcription factors SMAD2 and SMAD3 (Massagué et al., 2005) . Upon phosphorylation, SMAD2 and SMAD3 associate with SMAD4 and translocate to the nucleus, where they partner up with additional transcription factors (TFs) to regulate target gene expression (Massagué et al., 2005) . Remarkably, TGF-b universally relies on SMADs despite regulating cell-type-specific transcriptional programs (Massagué , 2012) . The current model is that cell-type-specific partner TFs guide SMADs to distinct genes, thus resulting in context-specific gene regulation and specific biological effects of TGF-b (Massagué , 2012; Mullen et al., 2011; Xu et al., 2015) .
Here, we mapped genome-wide SMAD3 binding patterns in BTICs that model the opposing effects of TGF-b (Bruna et al., 2012) . This showed that differential SMAD3 binding does not fully account for context-specific TGF-b target gene regulation, and further experiments revealed that distinct epigenetic states are responsible. We identify transcription factor LBH as a prototypical TGF-b target gene regulated by differential DNA methylation and show it is essential for the BTIC-promoting activity of TGF-b. Taken together, these data reveal an important role for epigenetic determinants in regulation of the context-specific actions of TGF-b in cancer.
RESULTS

SMAD3 Binding to Gene-Proximal Regions Mediates TGF-b-Dependent Gene Expression in BTICs
Two cell lines that we previously showed represent the opposing effects of TGF-b (Bruna et al., 2012) were used as BTIC model systems in all experiments: MDA-MB-231 for BTIC promoting, and HCC-1954 for BTIC suppressing (Figure 1A) . Cells were grown in suspension as mammosphere cultures to enrich for BTICs (Bruna et al., 2012; Dontu et al., 2003a Dontu et al., , 2003b . Confirming our previous data (Bruna et al., 2012) , the canonical TGF-b signaling cascade is intact and similarly activated by its ligand in both models, as shown by SMAD2 phosphorylation ( Figure 1B) .
The transcriptional responses associated with the opposing effects of TGF-b on BTICs were characterized by gene expression profiling. BTIC-enriched mammosphere cultures (hereafter referred to as ''BTICs'') were treated with TGF-b for varying amounts of time (1, 3, 6, and 24 hr) to capture both early and late transcriptional responses. Comparing the lists of TGF-b-dependent genes revealed that only a small fraction is commonly regulated in both BTIC types (''shared'' genes) ( Figure 1C ; Table S1 ). The vast majority of genes displayed cell-context-specific regulation, indicating that distinct and non-overlapping TGF-b-dependent transcriptional regulation occurs in BTICs with opposing (pro-oncogenic and tumor-suppressive) responses.
We previously showed that the BTIC-promoting and BTICsuppressing effects of TGF-b depend on SMADs (Bruna et al., 2012) . Hence, we hypothesized that SMADs mediate the TGF-b-dependent transcriptional regulation in both contexts. SMAD3 binding patterns in BTICs were mapped genome-wide after 3 hr of TGF-b exposure using chromatin immunoprecipitation and sequencing (ChIP-seq). We chose the 3-hr time point as it was the earliest at which significant TGF-b-dependent gene expression changes were detected in both models. Genomic annotation of SMAD3 binding sites showed a significant fraction of peaks (>30%) is directly associated with genes, with the remainder being at distal regulatory regions ( Figure 1D ).
We defined gene-proximal SMAD3 binding when peaks occurred within a genomic unit encompassing the 1,500 bp upstream of the transcription start site (TSS) to the end of the gene body. Comparing TGF-b-dependent and TGF-b-independent (background) gene sets revealed that both early-and late-responder genes are strongly enriched for gene-proximal SMAD3 binding in both BTIC types ( Figure 1E ). These data suggest that gene-proximal SMAD3 binding mediates TGFb-dependent gene regulation in both contexts.
Differential SMAD3 Binding Is Not the Sole Determinant of Context-Specific Gene Regulation by TGF-b
The prevailing model for TGF-b context-dependent transcriptional regulation assumes binding of SMAD3 to different genes in different cell types (Massagué , 2012; Mullen et al., 2011) . (E) Heatmaps showing gene expression dynamics upon TGF-b stimulation in each BTIC independently. Bar plots below each gene expression time point show the proportion of TGF-b-dependent genes at that particular time point that were detected as bound by SMAD3 in the ChIP-seq experiment (bar below the 1-hr time point in HCC-1954 is absent as zero genes were detected as significantly differentially expressed). Asterisks indicate statistical significance, which was determined with the chi-square test, using TGF-b-independent gene sets as background (refer to Supplemental Experimental Procedures for details).
Our data showed instead that a substantial proportion of SMAD3 binding sites are identical in both BTIC types (50% in MDA- MB-231 and 37% in HCC-1954) (Figure 2A ). Motif analysis identified a number of distinct DNA motifs under SMAD3 binding sites (Figures S1A and S1C), including ''canonical'' SMAD consensus motifs (Figures S1D and S1E) (Dennler et al., 1998; Jonk et al., 1998; Koinuma et al., 2009; Shi et al., 1998; Zawel et al., 1998) . The majority of identified motifs also corresponded to known SMAD binding partners ( Figure S1B ), which have been implicated in TGF-b responses by single gene studies (Gomis et al., 2006; Koinuma et al., 2009; Liberati et al., 1999; Massagué , 2012; Sundqvist et al., 2013; Xu et al., 2015; Zaidi et al., 2002) . These results indicate that SMAD3 associates with diverse co-factors that guide it to both shared and cell-type-specific genomic locations in BTICs.
Inspection of ChIP-seq profiles around BTIC context-specific TGF-b-dependent genes revealed that SMAD3 binding is not necessarily associated with the regulation of the underlying gene, but rather can adopt four different binding modes (Figure 2B) . For example, a gene regulated by TGF-b only in MDA-MB-231 BTICs (MDA-unique gene) can be: (1) uniquely bound by SMAD3 in MDA-MB-231 (binding mode 1), (2) uniquely bound by SMAD3 in HCC-1954 (binding mode 2), (3) commonly bound by SMAD3 in both cell types (binding mode 3), and (4) not bound by SMAD3 in either cell type (binding mode 4). The same applies to the TGF-b-dependent genes regulated uniquely in HCC-1954 BTICs (HCC-unique genes) ( Figure 2B , bottom panels). These results differ from those previously reported using non-malignant cellular models, where TGF-b's cell-context-specific genes are almost exclusively associated with cell-type-specific SMAD3 binding patterns (Mullen et al., 2011) .
We systematically investigated how these four SMAD3 binding modes contribute to gene regulation downstream of TGF-b. We found that TGF-b-dependent early-responder genes (derived 6 hr post-TGF-b treatment) are highly enriched for the common SMAD3 binding mode (mode 3) in both MDA- MB-231 and HCC-1954 BTICs (Figure 2C, upper table) . TGF-b-dependent late-responder genes (derived 24 hr post-TGF-b treatment) show enrichment of both common (mode 3) and cell-typeunique SMAD3 binding (modes 1 and 2; Figure 2C , lower table) . Notably, these BTIC type-unique SMAD3 binding events are associated with TGF-b-dependent genes in the corresponding model (MDA-unique genes with MDA-unique SMAD3 binding, and HCC-unique genes with HCC-unique SMAD3 binding) 24 hr after pathway activation. Genes not bound by SMAD3 in either cell type (mode 4) are relatively depleted in both the early and late TGF-b-responder genes, as could be expected based on the results presented in Figure 1E .
Based on the observed enrichment of the common SMAD3 binding mode in all gene groups and particularly in the early TGF-b responders, we conclude that cell-type-specific geneproximal SMAD3 binding is not the sole determinant of context-specific TGF-b transcriptional responses.
In embryonic stem cells and muscle and lymphocyte progenitors, SMAD3 occupies distinct, non-overlapping sites within the gene, even when binding to the same gene (Mullen et al., 2011) . To test if this also occurs in BTICs, we systematically categorized SMAD3 binding events into three classes: (1) uniquely present in MDA-MB-231 ( Figure 2D , red peak), (2) uniquely present in HCC-1954 ( Figure 2D , blue peak), and (3) present in identical position in both cell types ( Figure 2D , gray peaks). For each context-specific TGF-b-dependent gene, we derived a composite SMAD3 binding profile ( Figure 2D , right). This analysis revealed that only a small fraction of commonly bound genes (mode 3) possess mutually exclusive SMAD3 binding patterns ( Figures  2E and 2F , light blue boxes). In fact, most genes that are commonly bound by SMAD3 (mode 3) display either a mixed occupancy profile, where both identical and cell-type-specific binding sites are present, or an identical occupancy profile, where SMAD3 binds at identical coordinates within a given gene in both cell types ( Figures 2E and 2F ). These findings led us to hypothesize that for many genes (at least 422 MDA-unique genes and 264 HCC-unique genes) possessing remarkably similar SMAD3 binding patterns in BTICs (yellow boxes, Figures  2E and 2F ), other regulatory determinants might govern the context-specific transcriptional outputs of TGF-b.
We obtained similar results for SMAD3 binding events located distally to genes (Figures S2A-S2F; Supplemental Experimental Procedures); however, for simplicity, these are not presented in the Results section.
Context-Specific Epigenetic Landscape Modulates TGF-b/SMAD3-Dependent Transcriptional Regulation
In breast cancer, epigenetic modifications have characteristic, subtype-specific genomic patterns (Bediaga et al., 2010; Holm et al., 2010) . We therefore reasoned that cell-type-specific epigenetic landscapes in BTICs could contribute to shaping the TGF-b transcriptional responses. We profiled the chromatin configuration in BTICs by mapping RNA polymerase II (Pol II) binding, histone H3 lysine 27 acetylation (H3K27ac), histone H3 lysine 4 trimethylation (H3K4me3), and histone H3 lysine 27 trimethylation (H3K27me3) using ChIP-seq. We also mapped CpG DNA methylation using methyl-binding domain pull-down and sequencing (MBD-seq). These epigenetic marks were profiled in untreated BTIC cultures to determine whether the ''native'' chromatin configuration existing prior to TGF-b stimulation was what modulated the context-specific transcriptional response.
Peak-based analysis showed the genomic distribution of the epigenetic marks occurred in the expected patterns: Pol II peaks localized predominantly to enhancer and promoter regions, H3K4me3 peaks to promoter regions, H3K27ac peaks to enhancer and promoter regions, H3K27me3 peaks to intergenic domains, and DNA methylation peaks to gene-proximal elements ( Figure S3A ). Comparative analysis revealed that MDA-MB-231 and HCC-1954 BTICs harbor distinct epigenetic landscapes ( Figure S3B ).
Overlaying the epigenetic marks with SMAD3 binding data showed that SMAD3 binds to open chromatin (marked by H3K27ac, Pol II, and H3K4me3) and not to closed chromatin (marked by H3K27me3 and DNA methylation) ( Figure S3C ). Additionally, BTIC type-specific SMAD3 binding coincided with the type-specific patterns of Pol II and H3K27ac (Figure S3D) . This suggested that the pre-existing cell-type-specific chromatin context determines where SMAD3 binds upon TGF-b stimulation. -1954 (bottom) BTICs. SMAD3 adopts four modes of occupancy at these genes: bound in a cell-context-specific manner (modes 1 and 2), bound commonly in both BTIC types (mode 3), or not bound in either (mode 4).
(C) Genome-wide analysis showing the enrichment of each of the four SMAD3 binding modes (from B) at TGF-b-dependent genes. Gene expression data from 6-hr and 24-hr time points were used. Enrichment was calculated over SMAD3 binding distribution in the TGF-b-independent, background gene set (see We next asked whether the pre-existing BTIC type-specific gene-proximal chromatin patterns prime genes for TGFb-mediated regulation. To address this question, we combined differential binding analysis with gene set enrichment analysis ( Figure 3A ). This revealed that context-specific TGF-b-dependent genes are enriched for those with cell-type-specific epigenetic patterns, characterized by higher levels of gene-proximal open chromatin marks (H3K4me3, H3K27ac, and Pol II) (Figures 3B and 3C) and lower levels of repressive chromatin marks in the corresponding BTIC type ( Figure S3E ; HCC-unique genes depleted from H3K27me3; MDA-unique genes depleted from DNA methylation). We also noted that TGF-b-dependent genes unique to MDA-MB-231 showed higher levels of DNA methylation in HCC-1954 ( Figure 3B ). Together, these results show that distinct epigenetic landscapes in BTICs modulate context-specific responses to TGF-b: high levels of H3K4me3, H3K27ac, and Pol II in gene-proximal space permit, while TSS DNA methylation and H3K27me3 impede, TGF-b/SMAD3dependent regulation of gene expression.
We next asked whether these epigenetic differences in the gene-proximal space act in synergy with, or independently of, differential SMAD3 binding to control context-specific TGF-b target gene regulation. For this purpose, genes with differential levels of SMAD3 were defined using the same analysis as for the chromatin factors ( Figure 3A ). This enabled us to stringently detect genes with the most pronounced differences in SMAD3 binding intensity between BTICs. For each TGF-b context-specific gene group (MDA unique and HCC unique), we derived three sets of signatures: SMAD3-high gene set (genes that display higher levels of SMAD3 in the corresponding BTIC type), open chromatin-high gene set (genes with higher levels of either H3K4me3, H3K27ac or Pol II in the corresponding BTIC type), and DNA hypo-methylation gene set (genes with lower levels of TSS DNA methylation in the corresponding BTIC type) ( Table S2 ). Comparison of these gene sets in each BTIC type revealed that virtually all genes within the SMAD3high set (58 in MDA and 30 in HCC) also belong to the open chromatin-high gene set ( Figures 3D and 3E ). This shows that in order to achieve type-specific gene regulation, differential binding of SMAD3 is assisted by gene-proximal open chromatin configuration, as shown for IGDCC4 and GRAMD2 (epigenome-assisted TGF-b-regulated genes; Figures 4A and 4B ). Moreover, a substantial number of TGF-b-dependent genes in each BTIC type (401 MDA-unique genes; 181 HCC-unique genes) belonged to the open chromatin-high and/or DNA hypo-methylation sets, but not to the SMAD3-high set. Hence, the context-specific TGF-b-dependent regulation of the genes in this set is likely to be mediated by epigenetic differences (epigenome-directed TGF-b-regulated genes), as highlighted by ADAM8 and IGFBP5 ( Figures 4A and 4B ). This analysis also revealed that only a subset of SMAD3-high genes overlap with the DNA hypo-methylated set, suggesting that differential DNA methylation and differential SMAD3 binding appear to independently contribute to context-specific gene regulation by TGF-b.
Taken together, these results suggest that cell context-specific transcriptional responses to TGF-b are mediated by both SMAD3 and the epigenome. The epigenomic landscape primes genes for transcriptional regulation by TGF-b signaling, both in synergy with, and independently of, differential SMAD3 binding.
Differential DNA Methylation of LBH Impacts the BTIC-Promoting Effects of TGF-b
To functionally validate the impact of the epigenome on the opposing effects of TGF-b on BTICs, we focused on contextspecific TGF-b-dependent genes with differential DNA methylation. Interesting links have been proposed between normal developmental processes and breast cancer (Holm et al., 2010; , and therefore, we selected two genes encoding developmental TFs for further analysis: Limb Bud and Heart Development (LBH), and Vestigial-like family member 3 (VGLL3).
LBH and VGLL3 are induced by TGF-b in a SMAD2/3 dependent manner in BTICs from MDA-MB-231, but not in HCC-1954 (Figures S4A-S4D) . LBH is bound by SMAD3, and Pol II at an identical intragenic regulatory region in both cell types (Figure 5A) , but in HCC-1954, the TSS-proximal region is DNA methylated (coinciding with lack of Pol II binding) ( Figure 5A ). This suggests that context-specific regulation of LBH, despite remarkably similar SMAD3 binding, is dependent on the methylation status of its promoter (epigenome directed). In contrast, VGLL3 is bound by SMAD3 and Pol II only in MDA-MB-231 BTICs, while its TSS harbors DNA methylation only in HCC-1954 ( Figure 5B ). Hence, TGF-b-dependent regulation of VGLL3 is epigenome assisted.
To test if promoter methylation of LBH and VGLL3 determines their context-specific TGF-b-dependent transcriptional regulation, BTICs were treated with 5-aza-2 0 -deoxycytidine (5-aza-dC) prior to TGF-b stimulation, which resulted in reduction of overall methylation levels at these loci in HCC-1954 (Figures S4F and S4G) . In HCC-1954, 5-aza-dC treatment reactivated both LBH and VGLL3 expression, and TGF-b treatment further induced LBH, but not VGLL3 (Figures 5C, 5D , and S4E). This shows that promoter DNA methylation is sufficient to block TGF-b/SMAD3-mediated induction of LBH. Erasure of DNA methylation from VGLL3 failed to restore its TGF-b-dependent induction in HCC-1954, as predicted due to the absence of Supplemental Experimental Procedures for details). Note that the common binding mode (3) does not exclude SMAD3 binding sites that occur on the same genes but on different sites in the two BTICs. Also see Figure S2 . (D) Schematic of the gene-based SMAD3 binding analysis. For each gene in the genome, the number of context-specific SMAD3 binding sites (red and blue) and shared binding sites (gray) were calculated and represented as a composite profile. (E and F) Gene-based SMAD3 binding analysis on context-specific TGFb-dependent genes (performed as outlined in D). TGF-b-dependent genes 24 hr post-TGF-b stimulation were used. Genes are aligned along the x axis and grouped into distinct categories based on their SMAD3 composite profiles. SMAD3 binding modes are indicated below the plot in gray. Gene examples are highlighted with dashed lines. The light blue box marks genes with mutually exclusive SMAD3 binding patterns, and the yellow box marks those with predominantly similar or identical SMAD3 binding patterns in both BTICs. Also see Figure S2 . See Supplemental Experimental Procedures for details. SMAD3 binding at this locus. Taken together, these results confirm that the epigenetic configuration not only determines baseline gene expression levels, but it also controls TGF-b/ SMAD3-dependent transcriptional regulation.
To assess the functional implications of epigenome-directed and epigenome-assisted mechanisms, we investigated whether LBH and VGLL3 are required for the effects of TGF-b on BTICs. We knocked down their expression using short interfering RNAs (siRNAs), resulting in 80% and 50% reduction of LBH and VGLL3 transcript levels, respectively ( Figures S5A and S5B ). Mammosphere-initiating cell (MS-IC) and colony-forming cell (CFC) assays were used to test self-renewal and proliferation of BTICs (Bruna et al., 2012; Dontu et al., 2003a Dontu et al., , 2003b .
LBH knockdown in untreated cells reduced BTIC self-renewal and proliferation in both cell lines ( Figures 6A and 6B) , suggesting that LBH is required for baseline BTIC maintenance regardless of the response to TGF-b. In HCC-1954 BTICs, LBH transcripts are expressed at very low levels despite promoter methylation, and their reduction by siRNA treatment ( Figure S5A ) results in measurable effects in the BTIC assays ( Figures 6A and  6B) . These LBH transcripts are likely to originate from low levels of transcription initiated at methylated DNA molecules with variegated CpG methylation patterns (''epipolymorphisms''; Landan et al., 2012) , as determined by reduced representation bisulfite sequencing (RRBS) ( Figure 6C ). Thus, residual transcription initiated at epipolymorphic promoters can be functionally important.
In MDA-MB-231, LBH depletion impaired the BTIC-promoting effects of TGF-b by more than 2-fold ( Figures 6A and 6B ). In contrast, in HCC-1954, LBH depletion did not affect BTIC suppression by TGF-b ( Figures 6A and 6B ). In both cells lines, VGLL3 depletion had no effect on BTICs after TGF-b treatment ( Figures 6A and 6B ). Altogether, these results suggest that epigenome-directed gene co-regulation with SMAD3, as occurs with LBH, acts as a molecular switch that mediates the opposing effects of TGF-b on BTICs.
We previously showed that TGF-b specifically promotes BTIC activity only in Claudin low cell lines (Bruna et al., 2012) . We also showed that in normal mammary epithelium, TGF-b promotes mammary stem cells (the presumed cell of origin of Claudin low cancers), and it inhibits luminal progenitors (Bruna et al., 2012) . Interestingly, others have shown that in normal breast epithelial Differences between BTICs in the levels of each factor were defined based on differential binding analysis within the gene-proximal space (1,500 bp upstream of the TSS to gene end), apart from DNA methylation, for which only TSS-proximal regions were considered (À1,500 bp to +1,500 bp around the TSS). Gene set enrichment analysis was then conducted, testing the enrichment of differentially bound gene sets within the context-specific TGF-b-dependent gene sets (MDA-unique and HCC-unique genes tissue, LBH promotes stemness and inhibits differentiation (Lindley et al., 2015; Rieger et al., 2010) . We therefore sought evidence for a relevant role of LBH in both normal breast epithelium and in breast cancer. Analysis of gene expression data from normal human and mouse mammary epithelium revealed that LBH is highly expressed in the basal (stem cell-containing) compartment and is downregulated as cells differentiate along the luminal lineage ( Figures 6F, S5C , and S5D). Investigation of gene expression data from 1,980 primary breast cancers (Curtis et al., 2012) showed that LBH expression is highest in the Claudin low subtype ( Figure 6D ). In patients with Claudin low tumors, higher LBH expression correlates with worse survival ( Figure 6E ). These findings suggest that the BTIC context-specific TGF-b/ LBH observations we made in model cell lines are relevant to both normal and malignant primary tissue biology.
DISCUSSION
The mechanisms underlying the opposing TGF-b effects in cancer cells, being both pro-oncogenic and tumor suppressive, remain a significant challenge for inhibition of the pathway as a feasible cancer therapeutic strategy in the clinic. The current understanding is that TGF-b stimulation results in different responses in distinct cell types through the association of SMAD2/3 with specific SMAD cofactors (Massagué , 2008 (Massagué , , 2012 . Accordingly, in normal cells, along a developmental cascade, SMAD3 co-occupies distinct genomic locations in association with cell-type-specific master transcription factors: Oct4 in embryonic stem cells, Myod1 in myotubes, and PU.1 in pro-B cells (Mullen et al., 2011) . These cofactors are required for SMAD3 binding, and most TGF-b-regulated genes are bound by these master TFs (Mullen et al., 2011) . In other words, the currently accepted model suggests that master TFs are responsible for instructing the gene targets downstream of TGF-b signaling and thus determine its cell-type-specific effects (Mullen et al., 2011) . In cancer cells, no similar genome-wide studies have been conducted, but single-gene studies appear to show analogous findings: TF switches (where SMADs exchange binding partners) can occur and result in redirecting of SMADs from the promoters of tumor suppressor genes to promoters of oncogenes, concomitant with altered transcription of those target genes (Gomis et al., 2006; Seoane et al., 2004; Xu et al., 2015) .
Our results show for the first time that different SMAD3 binding patterns cannot fully account for the observed differences in the TGF-b-dependent transcriptional responses associated with promotion or suppression of BTICs. In fact, and surprisingly, the majority of BTIC context-specific TGF-b-dependent genes, particularly early-responder genes, are bound by SMAD3 in both contexts. While binding may occur in distinct locations A B along the gene, a large fraction of genes possessed coherent SMAD3 occupancy profiles, many with only identical SMAD3 binding sites. These results reveal that TGF-b-dependent celltype-specific transcriptional regulation in cancer cells is not universally mediated by differential SMAD3 binding. This prompted us to analyze whether additional regulatory mechanisms operating on chromatin modulate the context-specific target gene selection by TGF-b/SMAD3. Very recently, it has been reported that epigenetic configuration of somatic cells predisposes them to reprogramming fates (Pour et al., 2015) . Here we show that tumor initiating cells harbor distinct epigenetic landscapes that prime specific gene sets for regulation by TGFb. These distinct epigenetic configurations can act both in synergy with cell-type-specific SMAD3 binding (epigenome-assisted), and independently of cell-typespecific SMAD3 binding (epigenome-directed), to control TGFb/ SMAD3-dependent context-specific regulation of target genes (Figure 7) .
We propose that epigenome-directed priming in cancer cells might be a prevalent way of instructing context-specific TGFb effects. Cancer cells that originate in the same tissue (mammary epithelium in the case of BTICs), unlike cells from distinct tissue lineages, are likely to possess similar master TF wiring. But cancers with the same tissue of origin can possess markedly different Figure S4 .
(C and D) qRT-PCRs showing the expression of LBH and VGLL3 transcripts upon 5-aza-dC and TGF-b treatments. Cells were treated with 5-aza-dC for 5 days, seeded, and allowed to form mammospheres for 7 days, and then stimulated with TGF-b for 24 hr. Data were normalized to the housekeeping (RBM22) transcript levels and are presented as mean ± SD of three biological replicates. Asterisks indicate significant differences. ns, not significant (one-way ANOVA). Also see Figure S4 .
epigenomes, for example, DNA methylation of gene promoters (Holm et al., 2010) . Here, we reveal an unexpected similarity of SMAD3 binding patterns in BTICs with opposing transcriptional responses to TGF-b and show that context-specific TGF-b-dependent genes are frequently regulated by an epigenome-directed, DNAmethylation-dependent mechanism, rather than by differential SMAD3 binding. These results at the whole-genome level expand a previous observation in glioma, where the methylation status of PDGFB predisposes tumor cells for either an oncogenic or a tumor-suppressive response to TGF-b signaling (Bruna et al., 2007) . We have identified LBH, a regulator of epithelial differentiation in the mammary gland (Lindley et al., 2015; Rieger et al., 2010) , as a mediator required for the context-specific BTIC-promoting effects of TGF-b, depending on its cell-type-specific methylation state. The patterns of expression of LBH in normal mammary development and in human breast cancers are consistent with its role as a context-specific TGF-b target in primary tissues. We speculate that many epigenome-directed genes behave like LBH to mediate the context-specific effects of TGF-b in cancer.
The model we propose here (Figure 7) , that regulation of transcriptional programs by extracellular growth factors is dependent on the context-specific epigenomic landscapes of cancer cells, might not be specific to TGF-b and could have broader implications for the paracrine effects of the microenvironment on the malignant compartment of cancers.
EXPERIMENTAL PROCEDURES
Cell Manipulation and Mammosphere Cultures MDA-MB-231 and HCC-1954 breast cancer cell lines were enriched for BTICs by mammosphere cultures, as described previously (Bruna et al., 2012; Dontu et al., 2003a Dontu et al., , 2003b . To activate TGF-b signaling, mammospheres were treated with 0.1 nM recombinant TGF-b1. LBH, VGLL3, SMAD2 and SMAD3 levels were manipulated using siRNA pools (GE Cell Reports 13, 2480-2490, December 22, 2015 ª2015 The Authors 2487 Healthcare). To achieve global DNA demethylation, the cells were treated with 1 mM 5-aza-2 0 -deoxycytidine. For full details, see Supplemental Experimental Procedures.
Chromatin Immunoprecipitation and Sequencing
ChIP-seq was performed using a custom-developed protocol. Briefly, mammospheres (treated with 0.1 nM TGF-b for 3 hr for SMAD3 ChIP-seq, and untreated in all other experiments) were crosslinked for 45 min with Di(N-succinimidyl) glutarate (DSG) and 30 min with formaldehyde. Chromatin was extracted and then sheared using Covaris. Immunoprecipitation was performed with 10 mg of the corresponding antibodies and protein G agarose beads (Santa Cruz Biotechnology). Libraries were prepared with TruSeq LT kit (Illumina) and sequenced on HiSeq 2000 (Illumina). For the full protocol, see Supplemental Experimental Procedures.
DNA Methylation Profiling
For MBD-seq, methylated DNA was precipitated with recombinant methyl binding domain (MBD2b/MBD3L1) protein complex as part of MethylCollector Ultra kit (Active Motif), following the manufacturer's recommendations. Libraries were generated using TruSeq LT kit (Illumina) and sequenced on HiSeq 2000 (Illumina). Refer to Supplemental Experimental Procedures for details. RRBS was performed as described previously (Boyle et al., 2012) . Targeted bisulfite sequencing was performed using a custom-developed method (refer to Supplemental Experimental Procedures for details).
ChIP-Seq and MBD-Seq Data Analysis
Sequencing reads were filtered based on quality and aligned to the Human Genome Build 37 (hg19) using BWA ). For ChIP-seq, SMAD3 peaks were called using MACS , and SICER ) was used for all other factors profiled. For MBD-seq, bi-asymmetric-Laplace model (BALM) was used to call methylation peaks , and (MeD)IP-seq data analysis (MED-IPS) was used for quantitative analysis, whereby the data were normalized to the CG content . Downstream analysis of all datasets was performed in R statistical software (R Development Core Team, 2009), using edgeR (v3.8.5) for differential binding analysis and annovar (2014nov12) for annotation . Motif analysis was performed in MEME-ChIP Shehata et al. (2012) . Also see Figure S5 . (Robinson et al., 2011) . Refer to Supplemental Experimental Procedures for details.
Gene Expression Analysis
Gene expression upon TGF-b induction was profiled using Illumina HumanHT-12 BeadChips. Data were analyzed as previously described 
Western Blots
The cells were grown as mammospheres for 7 days then treated with TGF-b for 1 hr. Total cell lysates were collected, and 20 mg protein was run per condition on the 10% SDS-PAGE gels. Transfer to nitrocellulose membranes was conducted using semi-dry blotting system (Invitrogen). Membranes were blocked in 5% dried milk powder, 0.1% Tween-20 in PBS, and the following antibodies were used for protein detection: rabbit monoclonal against human phospho-SMAD2 (Ser 465/467) (Cell Signaling, 3108), rabbit polyclonal against human SMAD2/3 (Santa Cruz Biotechnology, sc-8332) and rabbit polyclonal against human b-actin (Abcam, ab8227).
Mammosphere-Initiating Cell and Colony-Forming Cell Assays
MS-IC and CFC assays were performed as previously described (Dontu et al., 2003a (Dontu et al., , 2003b . Refer to Supplemental Experimental Procedures for details.
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more binding in MDA more binding in HCC Genomic Position % Methylation (A) Identification of SMAD3 motifs in the SMAD3 ChIP-seq datasets. Motif analysis was performed in MEME.
(B) Putative SMAD3 partner TFs corresponding to DNA motifs detected in C (see below). Each circle represents putative co-factors (identified in MEME) whose motifs were found under MDA-unique (red), HCC-unique (blue) or Shared (grey) SMAD3 peaks. Note that even cell type-unique SMAD3 binding sites (peaks) can possess similar or identical DNA motifs, to which then identical TFs could bind, resulting in the overlap of the circles.
(C) Distinct DNA motifs detected under MDA-MB-231-unique SMAD3 binding sites, HCC-1954unique SMAD3 binding sites and shared SMAD3 binding sites. Red boxes indicate primary and secondary SMAD3 motifs identified by MEME, yellow boxes mark manually identified SMADbinding elements, whereas grey boxes indicate motifs unknown to associate with any factors to date. Motif enrichment analysis was performed in MEME. All motifs were significantly enriched in the corresponding datasets (e-value < 0.05).
(D) Manually identified SMAD motifs from (C). The nucleotide sequence shows experimentally determined SMAD binding sequence context and the corresponding studies are indicated above the sequence bar. CAGA-box is highlighted in yellow. Manually detected SMAD binding motifs are labelled below the sequence bar. All motifs that contain an uninterrupted AGAC sequence are marked with black bars. (A) Sketch of the analysis approach used to define SMAD3-bound enhancers by proximity association. All SMAD3 peaks falling within 20 kb up-and downstream of the gene boundaries were annotated to that gene.
(B) Genome-wide analysis showing the enrichment of each of the four binding modes of SMAD3bound distal enhancers on TGFβ-dependent genes. Gene expression data from 6h and 24h time-points were used. Enrichment was calculated over SMAD3 binding distribution in the TGFβ-independent, background gene set. Note that the common binding mode (3) does not exclude SMAD3 binding sites that are annotated to the same genes but occur on different sites in the two BTICs.
(C) Schematic of the nearest gene association approach. Each SMAD3 peak was associated with the nearest gene, excluding SMAD3 peaks in the gene-proximal space. For each TGFβ-dependent gene the number of context-specific SMAD3 binding sites (red and blue) and shared binding sites (grey) were then calculated and represented as a composite profile.
(D) and (E) Analysis of the SMAD3-bound enhancer profiles associated with context-specific TGFβdependent genes (performed as outlined in C). TGFβ-dependent genes 24h post-TGFβ stimulation were used. Genes are aligned along the x-axis, and grouped into distinct categories based on their SMAD3 composite profiles. SMAD3 binding modes are indicated below the plot in grey. Light blue box marks genes with mutually exclusive SMAD3 binding patterns, and yellow those with predominantly similar or identical SMAD3 binding patterns in both BTICs.
(F) Sketch of the potential limitations of the nearest gene association approach, where peaks that functionally represent the same regulatory element -a "superenhancer" (Whyte et al., 2013) might be annotated to different genes. and SMAD3 in combination. The cells were transfected upon seeding, allowed to form mammospheres for 7 days, and then treated with TGFβ for 6h (6h time point was chosen in order to assess the effects of SMAD2/3 depletion on LBH and VGLL3 simultaneously, as LBH is induced by TGFβ at 3h of treatment and VGLL3 at 6h of treatment). Gene expression was normalised to the housekeeping (RBM22) transcript levels. Mean of three biological replicates with SD is shown, asterisks indicate significant differences, ns = not significant (two-way ANOVA). Figure 5D . The data were normalised to the housekeeping PSMC4 transcript levels, and presented as mean ± standard deviation (SD), asterisks indicate significant differences (two-tailed t-test). The purpose of this experiment was to ensure that the diminished VGLL3 induction in MDA-MB-231 upon 5-aza-dC treatment is not a result of a technical problem or 5-aza-dC affecting the expression of the RBM22 housekeeper. (A) and (B) RT-qPCRs measuring LBH and VGLL3 transcript levels, respectively, upon siRNAmediated knockdown of LBH and VGLL3. The cells were treated with TGFβ and transfected with siRNAs at the moment of seeding, and then allowed to form mammospheres for 7 days. Gene expression was normalised to the housekeeping (PSMC4) transcript levels. Mean of three replicates with SD is shown, asterisks indicate significant differences (one-way ANOVA). (D) Genome browser screenshots showing transcript expression (mRNA-seq) signals over the LBH locus in distinct cell types of the normal mammary gland and in the variant human mammary epithelial (vHMEC) cells. Publicly available data were obtained from the Roadmap Epigenomics project (Kundaje et al., 2015) . All tracks are presented on the same scale for all the samples (not shown for simplicity).
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Supplemental Experimental Procedures Cell Propagation in Adherent Cultures
Breast cancer cell lines were first grown as adherent cultures for the purpose of propagation. MDA-MB-231 was grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin-streptomycin (Life Technologies), and HCC-1954 was grown in RPMI supplemented with 10% FBS and 100 U/ml penicillin-streptomycin. When reaching around 80% confluence, the cells were washed with PBS, then collected and singularised using 0.05% trypsin (Invitrogen). Trypsin was inactivated with the supplemented DMEM or RPMI media and the cells were collected and washed twice with PBS. After washing and for the purpose of seeding mammosphere cultures, the cells were re-suspended in an appropriate volume of DMEM-F12 media supplemented with 0.1 x B27, 20 ng/µl fibroblast growth factor (FGF), 20 ng/µl epidermal growth factor (EGF) and 100 U/ml penicillinstreptomycin.
Mammosphere Cultures
Mammosphere cultures were seeded at 1×10 5 cells/ml density. Mammospheres were grown in DMEM-F12 media supplemented with 0.1 x B27, 20 ng/µl FGF, 20 ng/µl EGF and 100 U/ml penicillinstreptomycin in ultra-low attachment plates (Corning).
TGFβ Pathway Manipulation
To stimulate the TGFβ pathway recombinant TGFβ1 protein (R&D Systems) was used at a final concentration of 0.1 nM (of the protein dimer). Duration of the stimulus is indicated in each experiment.
5-Aza-2'-deoxycytidine Treatment
To reduce global levels of DNA methylation, attached cells prior to mammosphere seeding were treated with 5-aza-2'-deoxycytidine (Sigma-Aldrich) at 1 µM final concentration during two consecutive passages. The third spike-in of 5-aza-2'-deoxycytidine was added immediately after seeding mammospheres. The spheres were grown for 7 days and then treated with TGFβ for 24h. Mammospheres were collected, washed twice with PBS and then each sample was split in two, one half for DNA extraction and one half for RNA extraction. For RNA extraction, pellets were lysed in Qiazol and RNA was extracted using miRNeasy kit (Qiagen). DNA was extracted using phenolchloroform extraction and ethanol precipitation.
siRNA-mediated Knock-down Experiments
To knock-down LBH, VGLL3, SMAD2 and SMAD3 in mammospheres, for each gene pools of 4 targeting siRNAs were used (GE Healthcare) at 25 nM final concentration. Non-targeting siRNA (GE Healthcare, D-001810-01-20) was used as a control. The cells were transfected immediately after seeding mammospheres at 1×10 5 cells/ml density and Dharmafect I (GE Healthcare) was used as the transfection reagent, according to the manufacturer's protocol. DMEM-F12 medium with 0.1 x B27, 20 ng/µl FGF, 20 ng/µl EGF but without any antibiotics was used for the whole duration of the experiment. In experiments with LBH and VGLL3 knock-downs, TGFβ was added to the cells at 0.1 nM final concentration two hours after transfection, and mammospheres were then allowed to form for 7 days. In SMAD2 and SMAD3 knock-down experiments, the mammospheres were allowed to form for 7 days, and TGFβ pathway was then activated for 6h by addition of exogenous TGFβ at 0.1 nM final concentration. RNA was extracted using miRNeasy kit (Qiagen).
MS-IC and CFC Assays
To assess modulation of self-renewal and proliferation capacity induced by LBH and VGLL3 knockdowns and TGFβ treatment, mammosphere initiating cell (MS-IC) assays and colony forming cell (CFC) assays were performed in parallel. siRNA transfections were performed as outlined above.
Seven days old mammospheres were span down at 1300 g and washed with PBS once. To obtain single cells, 1 ml of 0.05% trypsin was added to mammosphere pellets followed by incubation at 37°C for 2 minutes. Cells were then singularized by gentle pipetting. Trypsin was inactivated with 1 µl of 1000 x Trypsin Inhibitor (Roche) and diluted in 10 ml of PBS. Cells were centrifuged and the pellet was resuspended in an appropriate volume of DMEM-F12 media supplemented with 0.1x B27, 20 ng/µl FGF, 20 ng/µl EGF and 100 U/ml penicillin-streptomycin, to yield required dilutions of cells (1:2 for MDA-MB-231 and 1:4 for HCC-1954). Second generation spheres were seeded in ultra low attachment 96-well plates (Corning).
To image and count the number of mammospheres, a colorimetric assay was performed, where live cells were labeled on the 6th day from seeding with 1X tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), allowed to incorporate the dye over night, and imaged the following day on the Gel Count scanner (Oxford Optronix). Spheres were counted using automated Gel Count software. Data was analyzed with Prism 6.0 (GraphPad Software) and statistical significance was determined by ANOVA.
CFC assay was performed in parallel with second generation mammosphere assay. Singularized cells were seeded in 6 cm round collagen coated dishes (Fisher Scientific) at cell line specific densities (1:120 for MDA-MB-231 and 1:80 for HCC-1954), in 3 ml DMEM-F12 media supplemented with 5% FBS, 20 ng/µl FGF and 100 U/ml penicillin-streptomycin. The growth of colonies was monitored daily, and when reaching the appropriate density, all plates were washed twice with PBS, then fixed with methanol:acetone (1:1) for 30 s. The plates were then stained with 1:10 diluted Giemsa dye for 30 min, washed twice with PBS, allowed to air dry, and imaged on the Gel Count scanner (Oxford Optronix). PCR products were purified using 2X volume of solid phase reversible immobilisation (SPRI) beads (Illumina), two 80% ethanol washes and eluted in 25 µl of 10mM Tris-HCl, pH 8.5. Amplicons were then end-repaired and A-tailed in 30 µl reactions (1 µl of Klenow 5'->3' exo-(NEB), 3 µl of 10X NEB2 buffer, 1 µl of the dNTP solution (1mM dCTP, 1mM dGTP, 1mM dTTP and 10 mM ATP (in excess for A-tailing))), by incubation at 30°C for 20 min and 37°C for 20 min. Amplicons were purified from this reaction by addition of 2X volume of SPRI as above however at the last step the beads were retained in the 20 µl 10mM Tris-HCl, pH 8.5 elute and carried over through the subsequent reaction.
Amplicons were then ligated to barcoded methylated DNA adapters (TruSeq LT, Illumina) by adding 2 µl of 1:20 diluted TruSeq Illumina adapters, and then the master mix containing 1 µl T4 DNA Ligase (400,000 U/ml) (NEB), 3 µl T4 DNA Ligase buffer (NEB) and 4 µl nuclease-free water, giving the total 30 µl ligation reaction per sample. Barcoding was performed in such way that all amplicons from the same sample harbour one, same barcode. Ligation was carried out over night at 16°C and the following day it was inactivated by incubation at 65°C for 20 min. Ligation products were purified by addition of double volume of PEG-NaCl solution (20% w/v PEG 8000, 2.5M NaCl) to the beadcontaining ligation reaction, two 80% ethanol washes and elution in 10 µl of 10mM Tris-HCl, pH 8.5.
After purifying these 120 barcoded amplicons the quantity of each one was assessed using qPCR (KAPA Biosystems). These measurements were used to normalize sample amounts for pooling: amplicons representing the same region (e.g. LBH_1) from 12 different samples were pooled in equimolar ratios, giving rise to 10 pools, each representing a different genomic region. These 10 pools were then combined (without normalizing their amounts across each other, as some of them had very low yields), and purified with 2X volume of SPRI, two 80% ethanol washes and elution in 100 µl of 10mM Tris-HCl, pH 8.5, in order to bring down the volume of the solution.
This pooled library was then amplified with PfuTurbo Cx Hotstart DNA Polymerase (Agilent Technologies) in 14 PCR cycles (reaction conditions identical as above apart from the reaction volume which was now 200 µl). The amplified library was then purified with two consecutive SPRI purifications, one with 1.2X bead-to-sample volume ratio, and another with 1.5X bead-to-sample volume ratio, and both using two 80% ethanol washes and elution in 10mM Tris-HCl, pH 8.5. A small aliquot of the final library was taken and diluted for quality controls (1:10 dilution for Bioanalyser HS and 1:4,000 for qPCR (KAPA Biosystems)).
Sequencing was performed on MiSeq (Illumina) using 150 bp paired end sequencing (CRUK CI Genomics Core). Quality control and trimming was performed with FastQC and trim galore (Andrews, 2010) and reads were aligned to the Human Genome Build 37 (hg19) using Bismark (Krueger and Andrews, 2011) . Methylation of individual CpG sites was called using Bismark too. Downstream data analysis was performed in R and detection of differentially methylated CpGs was done fitting a logistic regression model to each CpG and correcting the p-values using FDR with a threshold of 0.1.
Reverse Transcription Quantitative PCR (RT-qPCR)
To generate cDNA, 100-400 ng of RNA per sample was mixed with 1µl of 50 µM custom made Oligo-(dT) 16 (5'-d(T) 16 VN-3', V= dA or dG or dC; N = dA or dG or dC or dT), and denatured at 65°C for 5 min. The samples were snap cooled on ice and reverse transcription was performed with Transcriptor First Strand cDNA Synthesis Kit (Roche), as recommended by the manufacturer. The samples were incubated at 25°C for 10 min, 55°C for 30 min and 85°C for 5 min.
Generated cDNAs were diluted with nuclease-free water in 1:10 ratio, and qPCR was performed using the TaqMan chemistry. Gene-specific TaqMan probes and TaqMan Fast Universal PCR Master Mix (Applied Biosystems) were used, as recommended by the manufacturer. The plates were run on Applied Biosystems 7900HT Fast Real-Time PCR system, with the fast cycling conditions (20s of denaturation at 95°C, followed by 40 cycles of 95°C for 1s and 60°C for 20s). Data were analyzed in SDS 2.4 software (Applied Biosystems), Excel (Microsoft) and Prism 6.0 (GraphPad Software). Statistical significance was determined using ANOVA.
Gene Expression Profiling using Illumna HumanHT-12 BeadChips
Gene expression analysis was performed on HumanHT-12 Expression BeadChips from Illumina, using 200 ng of RNA as a starting material. For each condition, biological triplicates were used.
